January 13, 2021 4:00 PM | By EFE
15 minutes. The United States will buy an additional 1.25 million doses of the monoclonal antibody cocktail to treat COVID-19 patients, one of the drugs from the pharmaceutical companies Roche (Switzerland) and Regeneron (USA) that was supplied to President Donald Trump when he tested positive.
As Roche reported in a statement, The purchase is the result of an agreement with the United States Departments of Health and Defense, which will increase the doses available in that country, the most affected in the pandemic, to 1.5 million.
Casirivimab and imdevimab are the drugs in this cocktail of antibodies. They are distributed by Regeneron in the US market and by Roche in the rest of the world.
The US Food and Drug Administration (FDA) recently approved the emergency use of these drugs. They are indicated mainly for high-risk patients (for example, the elderly) but who show moderate symptoms of COVID-19, so they do not require hospitalization.
According to Roche, the US will supply these doses of antibodies at no cost to patients, through health centers that, however, may require the payment of certain administrative fees.
The acquisition, the amount of which was not disclosed, will be completed during the first six months of this year.
Trials in the countries
Regeneron scientists developed casirivimab and imdevimab. It is used to block the infectivity of the SARS-CoV-2 coronavirus, which causes COVID-19. Currently, countries such as the United Kingdom, are testing it.
Faced with a large number of COVID-19 vaccine candidates, there were fewer results in the search for effective treatments against the disease. Some of them, initially tested with the approval of the World Health Organization, were abandoned due to their poor results.
The most effective for now is dexamethasone. This corticosteroid, very affordable in the international market, is recommended only for the treatment of severe cases of COVID-19.